Lumida
/INGN
⌘K
Inogen Inc

Inogen Inc

INGN
$5.31USD↑+2.51%+0.13 today

MARKET CAP

140.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$5
$9

AI Summary

Stalk
Buy NowMedium

In a Stage 2 advancing environment, the recent Momentum Breakout above minor resistance confirms fresh demand and underpins a bullish medium-term bias. Price is riding above rising 9 and 21 EMAs and has just cleared the ~6.80 resistance zone on strong volume. Short-term momentum favors continuation, though Extreme Overbought conditions warrant cautious management. Execution favors immediate participation in the breakout zone or a shallow pullback into the rising EMAs for continuation exposure.

  • ↑Q2 2026 revenue $95.1M (+3% YoY) with breakeven earnings and 45.6% gross margin
  • ↑International sales surged 14.8% YoY, easing U.S. market pressures
  • ↓U.S. sales dropped 2.3% with rental revenues down 11.8%, stalling domestic growth
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Inogen, Inc. (NASDAQ: INGN) is an emerging leader in the home healthcare sector, specializing in portable oxygen concentrators and respiratory therapy products. The company has positioned itself within the ongoing trend of increasing respiratory health solutions, benefiting from an aging population and rising chronic respiratory conditions. Despite facing challenges in its U.S. sales, particularly in rental revenues, Inogen continues to pursue growth opportunities in international markets, showcasing robust demand for its products beyond domestic borders.

Bull says

  • ↑Q2 2026 revenue $95.1M (+3% YoY) with breakeven earnings and 45.6% gross margin
  • ↑International sales surged 14.8% YoY, easing U.S. market pressures
  • ↑Adjusted EBITDA outlook raised to ~$4M, reflecting effective cost controls
  • ↑New Voxi and Aurora CPAP masks gaining global traction and product mix diversification
  • ↑Aging population and rising healthcare spending underpin long-term respiratory demand
  • ↑Quality metrics and adequate liquidity suggest operational resilience

Bear says

  • ↓U.S. sales dropped 2.3% with rental revenues down 11.8%, stalling domestic growth
  • ↓Full-year top-line outlook trimmed from $366–373M to $355–361M, raising execution concerns
  • ↓Negative growth and profitability factors point to challenges in revenue expansion and margins
  • ↓High stock volatility may deter conservative investors amid uneven results
  • ↓Elevated short interest underscores market skepticism about near-term catalysts
  • ↓Competitive pressures in healthcare tech require ongoing R&D investment to maintain edge

Investment themes with INGN

Health Care Equipment & Supplies↑ +0.40%

Clinical instruments and devices powering patient care

ABT · ISRG · SYK
High Dividend Yield↑ +0.15%

Companies paying above-average dividends

AISP · SMR · NWL

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-09-2025bullish

Transcript signals

Bull points

  • I'm pleased that our organization made meaningful steps in the right direction during the first quarter. Our resilience and progress are a testament to the strength of our team at Inogen. We recognize there is much work to be done, but we will continue to execute against our strategic goals and remain excited about the future.
  • I'm pleased that our organization made meaningful steps in the right direction during the first quarter. Our resilience and progress are a testament to the strength of our team at Inogen. We recognize there is much work to be done, but we will continue to execute against our strategic goals and remain excited about the future.
Read full transcript analysis ›